NCT02140151View on ClinicalTrials.gov

Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

September 17, 2014

Primary Completion Date

July 9, 2020

Study Completion Date

July 9, 2020

Conditions
Age-related Macular Degeneration
Interventions
DRUG

Ranibizumab 0.5mg

Trial Locations (4)

21237

Elman Retina, Baltimore

57701

Black Hills Regional Eye Institute, Rapid City

92211

Southern California Desert Retina Consultants, Palm Desert

94040

Northern California Retina Vitreous Associates, Mountain View

All Listed Sponsors
lead

Southern California Desert Retina Consultants, MC

OTHER

NCT02140151 - Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter